{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:44:18Z","timestamp":1792759458519,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"janssen scientific affairs, llc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12325-021-01883-8","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T07:02:51Z","timestamp":1628924571000},"page":"4961-4974","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Real-World Adherence to Antiretroviral Therapy Among HIV-1 Patients Across the United States"],"prefix":"10.1007","volume":"38","author":[{"given":"Grace A.","family":"McComsey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Lingohr-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prina","family":"Donga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"key":"1883_CR1","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.15585\/mmwr.mm6848e1","volume":"68","author":"NS Harris","year":"2019","unstructured":"Harris NS, Johnson AS, Huang Y-LA, et al. Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis\u2014United States, 2013\u20132018. MMWR Morb Mortal Wkly Rep. 2019;68:1117\u201323.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1883_CR2","unstructured":"Centers for Disease Control and Prevention. Table 11. Human immunodeficiency virus (HIV) diagnoses, by year of diagnosis and selected characteristics: United States, 2013\u20132018. https:\/\/www.cdc.gov\/nchs\/data\/hus\/2019\/011-508.pdf. Accessed 22 Mar 2021."},{"key":"1883_CR3","unstructured":"Centers for Disease Control and Prevention. HIV surveillance report. Last updated June 2020. https:\/\/www.cdc.gov\/hiv\/statistics\/overview\/index.html. Accessed 22 Mar 2021."},{"key":"1883_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.puhe.2016.05.004","volume":"139","author":"J Poorolajal","year":"2016","unstructured":"Poorolajal J, Hooshmand E, Mahjub H, Esmailnasab N, Jenabi E. Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis. Public Health. 2016;139:3\u201312.","journal-title":"Public Health"},{"key":"1883_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/hiv.12421","volume":"18","author":"S Teeraananchai","year":"2017","unstructured":"Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18:256\u201366.","journal-title":"HIV Med"},{"key":"1883_CR6","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1600693","volume":"375","author":"MS Cohen","year":"2016","unstructured":"Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375:830\u20139.","journal-title":"N Engl J Med"},{"key":"1883_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S192735","volume":"13","author":"F Altice","year":"2019","unstructured":"Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475\u201390.","journal-title":"Patient Prefer Adherence"},{"key":"1883_CR8","unstructured":"Pharmacy Quality Alliance. PQA Measure Overview. 2019. https:\/\/www.pqaalliance.org\/assets\/Measures\/2019_PQA_Measure_Overview.pdf. Accessed 22 Mar 2021."},{"key":"1883_CR9","unstructured":"US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Treatment goals. Updated January 28, 2016. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/treatment-goals?view=full. Accessed 18 May 2021."},{"key":"1883_CR10","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf. Accessed 18 May 2021."},{"key":"1883_CR11","first-page":"242","volume":"22","author":"SS Sutton","year":"2016","unstructured":"Sutton SS, Hardin JW, Bramley TJ, D\u2019Souza AO, Bennett CL. Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks. Am J Manag Care. 2016;22:242\u20138.","journal-title":"Am J Manag Care"},{"key":"1883_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1089\/apc.2017.0081","volume":"31","author":"J Yager","year":"2017","unstructured":"Yager J, Faragpm J, McGuey L, et al. Relationship between single tablet antiretroviral regimen and adherence to antiretroviral and non-antiretroviral medications among Veterans\u2019 Affairs patients with human immunodeficiency virus. AIDS Patient Care STDs. 2017;31:370\u20136.","journal-title":"AIDS Patient Care STDs"},{"key":"1883_CR13","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2147\/PPA.S207908","volume":"13","author":"DM Hines","year":"2019","unstructured":"Hines DM, Ding Y, Wade RL, Beaubrun A, Cohen JP. Treatment adherence and persistence among HIV-1 patients newly starting treatment. Patient Pref Adherence. 2019;13:1927\u201339.","journal-title":"Patient Pref Adherence"},{"key":"1883_CR14","first-page":"88","volume":"25","author":"A Kangethe","year":"2019","unstructured":"Kangethe A, Polson M, Lord TC, Evangelatos T, Oglesby A. Real-world health plan data analysis: key trends in medication adherence and overall costs in patients with HIV. J Manag Care Spec Pharm. 2019;25:88\u201393.","journal-title":"J Manag Care Spec Pharm"},{"key":"1883_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","volume":"17","author":"J Cohen","year":"2020","unstructured":"Cohen J, Beaubrun A, Bashyal R, Huang A, Li J, Baser O. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries. AIDS Res Ther. 2020;17:12.","journal-title":"AIDS Res Ther"},{"key":"1883_CR16","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1007\/s10461-020-02937-8","volume":"24","author":"C Benson","year":"2020","unstructured":"Benson C, Wang X, Dunn KJ, et al. Antiretroviral adherence, drug resistance, and the impact of social determinants of health in HIV-1 patients in the US. AIDS Behav. 2020;24:3562\u201373.","journal-title":"AIDS Behav"},{"key":"1883_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25382","volume":"22","author":"B Youn","year":"2019","unstructured":"Youn B, Shireman TI, Lee Y, Gal\u00e1rraga O, Wilson IB. Trends in medication adherence in HIV patients in the US, 2001 to 2012: an observational cohort study. J Int AIDS Soc. 2019;22: e25382.","journal-title":"J Int AIDS Soc"},{"key":"1883_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/ofid\/ofv133.291","volume":"2","author":"J Forlenza","year":"2015","unstructured":"Forlenza J, Brown K, Shprecher A, et al. An evaluation of patient characteristics, duration on antiretrovirals (ARVs) and adherence in a large, insured United States population receiving HIV treatment between 2010 and 2014. Open Forum Infect Dis. 2015;2:416.","journal-title":"Open Forum Infect Dis"},{"key":"1883_CR19","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.2147\/PPA.S272211","volume":"14","author":"W Chow","year":"2020","unstructured":"Chow W, Donga P, C\u00f4t\u00e9-Sergen A, et al. Treatment patterns and predictors of adherence in HIV patients receiving single- or multiple-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide. Patient Prefer Adherence. 2020;14:2315\u201326.","journal-title":"Patient Prefer Adherence"},{"key":"1883_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003361","volume":"95","author":"WM Bezabhe","year":"2016","unstructured":"Bezabhe WM, Chalmers L, Berznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure. Medicine (Baltimore). 2016;95: e3361.","journal-title":"Medicine (Baltimore)"},{"key":"1883_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/QAI.0000000000002142","volume":"82","author":"KK Byrd","year":"2019","unstructured":"Byrd KK, Hou JG, Hazen R, et al. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Synd. 2019;82:245\u201351.","journal-title":"J Acquir Immune Defic Synd"},{"key":"1883_CR22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s13104-017-2764-9","volume":"10","author":"AM Aldous","year":"2017","unstructured":"Aldous AM, Castel AD, Parenti DM. DC Cohort Executive Committee. Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999\u20132014. BMC Res Notes. 2017;10:474.","journal-title":"BMC Res Notes"},{"key":"1883_CR23","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/cid\/ciw128","volume":"62","author":"AU Scherrer","year":"2016","unstructured":"Scherrer AU, von Wyl V, Yang WL, et al. Emergence of acquired HIV-1 drug resistance almost stopped in Switzerland: a 15-Year prospective cohort analysis. Clin Infect Dis. 2016;62:1310\u20137.","journal-title":"Clin Infect Dis"},{"key":"1883_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1089\/aid.2019.0111","volume":"36","author":"E Lathouwers","year":"2020","unstructured":"Lathouwers E, Wong EY, Brown K, et al. Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in adults living with HIV-1 from the Phase III randomized AMBER and EMERALD trials. AIDS Res Hum Retroviruses. 2020;36:48\u201357.","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01883-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01883-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01883-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:31:54Z","timestamp":1630438314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01883-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1883"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01883-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,14]]},"assertion":[{"value":"28 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}